Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 11, 2013, Pages 1186-1191

  Weinstock Guttman, Bianca ^a   Zivadinov, Robert ^a   Horakova, Dana ^b   Havrdova, Eva ^b   Qu, Jun ^c   Shyh, Grace ^c   Lakota, Elizabeth ^c   O'Connor, Kerri ^c   Badgett, Darlene ^c   Tamaño Blanco, Miriam ^c   Tyblova, Michaela ^b   Hussein, Sara ^a   Bergsland, Niels ^a   Willis, Laura ^a   Krasensky, Jan ^b   Vaneckova, Manuela ^b   Seidl, Zdenek ^b   Ramanathan, Murali ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CALCIFEDIOL; CALCITRIOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIGOCLONAL BAND; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BODY MASS; BRAIN SIZE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DEMYELINATING DISEASE; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

EID: 84885649688     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304740     Document Type: Article

References (39)

1. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-7.
2. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127.
3. Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002;106:109-12. (Pubitemid 34831927)
4. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, et al. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009;15:399-402.
5. Henninger DD, Gerritsen ME, Granger DN. Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circ Res 1997;81:274-81. (Pubitemid 27342495)
6. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011;12:204-12.
7. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31. (Pubitemid 13158528)
9. Sundstrom P, Nystrom L, Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol 2008;15:579-83. (Pubitemid 351677503)
10. Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005;330:277.
11. Duan X, Weinstock-Guttman B, Wang H, et al. Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem 2010;82:2488-97.
12. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47. (Pubitemid 32947383)
13. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuro Image 2012;59:331-9.
14. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84. (Pubitemid 43739821)
15. Johansson J, Carlson LA, Landou C, et al. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174-82.
16. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol 1999;22(6 Suppl):II21-7. (Pubitemid 29265096)
17. Ferretti G, Bacchetti T, Negre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7. (Pubitemid 41721062)
18. Morra VB, Coppola G, Orefice G, et al. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology 2004;62:829-30. (Pubitemid 38298972)
19. Byskosh PV, Reder AT. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996;1:262-9. (Pubitemid 126701318)
20. Sena A, Pedrosa R, Ferret-Sena V, et al. Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clin Chem Lab Med 2000;38:209-13. (Pubitemid 30386690)
21. Tallantyre EC, Dixon JE, Donaldson I, et al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. Neurology 2011;76:534-9.
22. Wang CY, Chang TC, Chen MF. Associations between subclinical thyroid disease and metabolic syndrome. Endocr J 2012;59:911-7.
23. Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012;96:269-81.
24. Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010;21:499-506.
25. Horton M, Rudick RA, Hara-Cleaver C, et al. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology 2010;35:83-90.
26. Silvestroff L, Bartucci S, Pasquini J, et al. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol 2012;235:357-67.
27. D'Intino G, Lorenzini L, Fernandez M, et al. Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism. J Neuroendocrinol 2011;23:778-90.
28. Billon N, Jolicoeur C, Tokumoto Y, et al. Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TRalpha1). EMBO J 2002;21:6452-60. (Pubitemid 35448423)
29. Dugas JC, Ibrahim A, Barres BA. The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration. Mol Cell Neurosci 2012;50:45-57.
30. Weinstock-Guttman B, Zivadinov R, Ramanathan M. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci 2011;311:86-91.
31. Stewart N, Simpson S Jr, van der Mei I, et al. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254-60.
32. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011;50:303-12.
33. Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res 1989;30:379-86. (Pubitemid 19082066)
34. Sellner J, Weber MS, Vollmar P, et al. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther 2010;6:362-73.
35. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8. (Pubitemid 38625664)
36. Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009;72:1989-93.
37. Waubant E, Pelletier D, Mass M, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology; 2012;78:1171-8.
38. Markovic-Plese S, Jewells V, Speer D. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2009;72:1965; author reply -6.
39. Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011;10:691-701.